CYTOKINETICS INCCYTKEarnings & Financial Report
Cytokinetics, Incorporated, is a biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function.
CYTK Q4 FY2025 Key Financial Metrics
Revenue
$17.8M
Gross Profit
N/A
Operating Profit
$-178.4M
Net Profit
$-183.0M
Gross Margin
N/A
Operating Margin
-1004.6%
Net Margin
-1030.9%
YoY Growth
4.9%
EPS
$-1.51
CYTOKINETICS INC Q4 FY2025 Financial Summary
CYTOKINETICS INC reported revenue of $17.8M (up 4.9% YoY) for Q4 FY2025, with a net profit of $-183.0M (down 22.0% YoY) (-1030.9% margin).
Key Financial Metrics
| Total Revenue | $17.8M |
|---|---|
| Net Profit | $-183.0M |
| Gross Margin | N/A |
| Operating Margin | -1004.6% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
CYTOKINETICS INC Q4 FY2025 revenue of $17.8M breaks down across 2 segments, led by Other at $9.1M (51.1% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Other | $9.1M | 51.1% |
| Collaboration Revenues | $8.7M | 48.9% |
CYTOKINETICS INC Revenue by Segment — Quarterly Trend
CYTOKINETICS INC revenue by segment across the last 4 reported quarters, showing how each business line (such as Other and Collaboration Revenues) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q2 FY2025 | Q4 FY2024 | Q2 FY2022 |
|---|---|---|---|---|
| Other | $9.1M | — | $1.9M | — |
| Collaboration Revenues | $8.7M | $2.4M | — | — |
CYTOKINETICS INC Quarterly Revenue & Net Profit History
CYTOKINETICS INC results over the last 4 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $17.8M | +4.9% | $-183.0M | -1030.9% |
| Q2 FY2025 | $66.8M | +26714.9% | $-134.4M | -201.2% |
| Q4 FY2024 | $16.9M | +912.4% | $-150.0M | -886.3% |
| Q2 FY2022 | $89.0M | +3029.4% | $-19.8M | -22.3% |
Income Statement
| Q2 2022 | Q4 2024 | Q2 2025 | Q4 2025 | |
|---|---|---|---|---|
| Revenue | $89.0M | $16.9M | $66.8M | $17.8M |
| YoY Growth | 3029.4% | 912.4% | 26714.9% | 4.9% |
Balance Sheet
| Q2 2022 | Q4 2024 | Q2 2025 | Q4 2025 | |
|---|---|---|---|---|
| Assets | $771.7M | $1.40B | $1.23B | $1.42B |
| Liabilities | $660.3M | $1.54B | $1.59B | $2.08B |
| Equity | $111.4M | $-135.4M | $-368.7M | $-659.6M |
Cash Flow
| Q2 2022 | Q4 2024 | Q2 2025 | Q4 2025 | |
|---|---|---|---|---|
| Operating CF | $-90.5M | $-65.6M | $-128.2M | $-142.7M |